Area of Expertise

Drug Discovery and Development is the multidisciplinary journey through which a promising scientific idea is transformed into a therapeutic product with demonstrated quality, safety, and efficacy. At Apex Pharmacology Institute (API), we provide education across this continuum, beginning with disease biology and unmet medical need, target identification and validation, assay development, hit identification, screening, hit-to-lead progression, lead optimization, and candidate selection. Training integrates the disciplines that drive modern discovery—including medicinal chemistry, molecular and cellular pharmacology, efficacy models, ADME, drug metabolism and transport, pharmacokinetics, pharmacodynamics, PK/PD relationships, toxicology, formulation, and early assessment of developability. Learners gain an integrated perspective on how potency and selectivity must be balanced with exposure, safety, physicochemical properties, and other characteristics to identify candidates with a realistic potential to become medicines.

From candidate selection, our focus moves into preclinical and translational development, where experimental evidence is assembled to support progression into humans. Topics include in vitro and in vivo pharmacology, animal model selection, preclinical PK and toxicokinetics, safety pharmacology, toxicology, bioanalysis, formulation and route-of-administration considerations, dose–exposure relationships, biomarkers, allometric scaling and other translational approaches, first-in-human dose prediction, and integration of PK/PD and safety margins. We examine the strategic decisions behind go/no-go criteria, candidate progression, Investigational New Drug (IND)-enabling studies, regulatory interactions, and preparation for first-in-human development, helping learners appreciate how data from multiple disciplines converge to inform critical development decisions.

Our training follows promising candidates into clinical development, regulatory evaluation, approval, and post-marketing lifecycle management, connecting early discovery decisions with Phase I–III clinical development, dose selection and optimization, clinical pharmacology, efficacy and safety evaluation, regulatory submissions, benefit–risk assessment, pharmacovigilance, and post-approval studies. Content can also address contemporary approaches such as biologics, targeted therapies, precision medicine, biomarkers and companion diagnostics, model-informed drug development, artificial intelligence and computational approaches, and emerging therapeutic platforms. 

Designed for students, academic researchers, clinicians, pharmaceutical and biotechnology scientists, and professionals entering or advancing within drug development, API presents drug discovery and development not as isolated scientific disciplines, but as an interconnected decision-making process—from identifying a therapeutic opportunity to delivering a safe and effective medicine to patients.